Literature DB >> 24301609

Enhanced nicotine metabolism in HIV-1-positive smokers compared with HIV-negative smokers: simultaneous determination of nicotine and its four metabolites in their plasma using a simple and sensitive electrospray ionization liquid chromatography-tandem mass spectrometry technique.

Ravinder Earla1, Anusha Ande, Carole McArthur, Anil Kumar, Santosh Kumar.   

Abstract

Smoking is approximately three times more prevalent in HIV-1-positive than HIV-negative individuals in the United States. Nicotine, which is the major constituent of tobacco, is rapidly metabolized mainly by cytochrome P450 (CYP2A6) to many metabolites. In this study, we developed a simple, fast, and sensitive electrospray ionization liquid chromatography-tandem mass spectrometry method using a strong cation solid phase extraction, and determined the concentration of nicotine and its four major metabolites (cotinine, nornicotine, norcotinine, and trans-3'-hydroxycotinine) in the plasma of HIV-1-positive and HIV-negative smokers. The multiple reaction monitoring transitions for nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine, norcotinine, nicotine-d4, and cotinine-d3 were selected at mass-to-charge ratios of 163.3/117.1, 177.5/80.3, 193.2/80.1, 149.5/132.3, 163.4/80.3, 167.3/121.4, and 180.3/101.2, respectively. The lower limit of quantitation for nicotine and its metabolites was 0.53 ng/ml, which is relatively more sensitive than those previously reported. The concentration of nicotine was detected 5-fold lower in HIV-1-positive smokers (7.17 ± 3.8 ng/ml) than that observed in HIV-negative smokers (33.29 ± 15.4 ng/ml), whereas the concentration of the metabolite nornicotine was 3-fold higher in HIV-1-positive smokers (6.8 ± 2.9 ng/ml) than in HIV-negative smokers (2.3 ± 1.2 ng/ml). Although it was statistically nonsignificant, the concentration of the metabolite cotinine was also higher in HIV-1-positive smokers (85.6 ± 60.5 ng/ml) than in HIV-negative smokers (74.9 ± 40.5 ng/ml). In conclusion, a decrease in the concentration of nicotine and an increase in the concentration of its metabolites in HIV-1-positive smokers compared with HIV-negative smokers support the hypothesis that nicotine metabolism is enhanced in HIV-1-positive smokers compared with HIV-negative smokers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24301609      PMCID: PMC3912541          DOI: 10.1124/dmd.113.055186

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

Review 1.  The role of monocytes and macrophages in the pathogenesis of HIV-1 infection.

Authors:  Katherine Kedzierska; Suzanne M Crowe
Journal:  Curr Med Chem       Date:  2002-11       Impact factor: 4.530

2.  Measuring nicotine intake in population surveys: comparability of saliva cotinine and plasma cotinine estimates.

Authors:  Martin J Jarvis; Paola Primatesta; Bob Erens; Colin Feyerabend; Andrew Bryant
Journal:  Nicotine Tob Res       Date:  2003-06       Impact factor: 4.244

3.  Iron and oxidative stress as a mechanism for the enhanced production of human immunodeficiency virus by alveolar macrophages from otherwise healthy cigarette smokers.

Authors:  J R Boelaert; J Piette; G A Weinberg; C Sappey; E D Weinberg
Journal:  J Infect Dis       Date:  1996-04       Impact factor: 5.226

4.  2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor.

Authors:  S S Hecht; J B Hochalter; P W Villalta; S E Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 5.  Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Authors:  Anusha Ande; Carole McArthur; Anil Kumar; Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-07-04       Impact factor: 4.481

6.  Oxidative stress in human immunodeficiency virus infection.

Authors:  N Israël; M A Gougerot-Pocidalo
Journal:  Cell Mol Life Sci       Date:  1997-12       Impact factor: 9.261

7.  Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon.

Authors:  Pierre Bodelle; Ana Vallari; Ruthie Coffey; Carole P McArthur; Mathilde Beyeme; Sushil G Devare; Gerald Schochetman; Catherine A Brennan
Journal:  AIDS Res Hum Retroviruses       Date:  2004-08       Impact factor: 2.205

8.  Comparison of tests used to distinguish smokers from nonsmokers.

Authors:  M J Jarvis; H Tunstall-Pedoe; C Feyerabend; C Vesey; Y Saloojee
Journal:  Am J Public Health       Date:  1987-11       Impact factor: 9.308

9.  Enhanced production of human immunodeficiency virus type 1 by in vitro-infected alveolar macrophages from otherwise healthy cigarette smokers.

Authors:  R A Abbud; C K Finegan; L A Guay; E A Rich
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226

10.  Metabolism of nicotine to cotinine studied by a dual stable isotope method.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1994-11       Impact factor: 6.875

View more
  23 in total

1.  Brief Report: Rate of Nicotine Metabolism and Tobacco Use Among Persons With HIV: Implications for Treatment and Research.

Authors:  Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

2.  Delivery and implementation of an algorithm for smoking cessation treatment for people living with HIV and AIDS.

Authors:  Karen L Cropsey; Madelyne C Bean; Louise Haynes; Matthew J Carpenter; Lauren E Richey
Journal:  AIDS Care       Date:  2019-06-07

3.  Differences in the rate of nicotine metabolism among smokers with and without HIV.

Authors:  Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

4.  Chronic Effects of Ethanol and/or Darunavir/Ritonavir on U937 Monocytic Cells: Regulation of Cytochrome P450 and Antioxidant Enzymes, Oxidative Stress, and Cytotoxicity.

Authors:  P S S Rao; Santosh Kumar
Journal:  Alcohol Clin Exp Res       Date:  2016-01       Impact factor: 3.455

5.  Cytokine profiling of exosomes derived from the plasma of HIV-infected alcohol drinkers and cigarette smokers.

Authors:  Sunitha Kodidela; Sabina Ranjit; Namita Sinha; Carole McArthur; Anil Kumar; Santosh Kumar
Journal:  PLoS One       Date:  2018-07-27       Impact factor: 3.240

Review 6.  Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.

Authors:  Santosh Kumar; P S S Rao; Ravindra Earla; Anil Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-12-24       Impact factor: 4.481

7.  Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats.

Authors:  Sriram Gunda; Ravinder Earla; Kishore Cholkar; Ashim K Mitra
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-19       Impact factor: 2.441

Review 8.  Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors:  Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-13       Impact factor: 4.147

9.  Enhanced methamphetamine metabolism in rhesus macaque as compared with human: an analysis using a novel method of liquid chromatography with tandem mass spectrometry, kinetic study, and substrate docking.

Authors:  Ravinder Earla; Santosh Kumar; Lei Wang; Steven Bosinger; Junhao Li; Ankit Shah; Mohitkumar Gangwani; Anantha Nookala; Xun Liu; Lu Cao; Austin Jackson; Peter S Silverstein; Howard S Fox; Weihua Li; Anil Kumar
Journal:  Drug Metab Dispos       Date:  2014-10-09       Impact factor: 3.922

10.  Impact of Tobacco Smoke in HIV Progression: a Major Risk Factor for the Development of NeuroAIDS and Associated of CNS Disorders.

Authors:  Aditya Bhalerao; Luca Cucullo
Journal:  Z Gesundh Wiss       Date:  2019-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.